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A C-terminal fragment of rat pancreastatin, a 26 residue peptide amide and a fragment without a C-terminal amide were synthesized byFmoc-based 
solid phase methods and their biological activities were compared. The rat C-terminal fragment inhibited pancreatic exocrine secretions produced 
by the intravenous injection of 2-deoxy-D-glucose (a central vagal nerve stimulation), whereas the fragment without a C-terminal amide showed 
no effect on pancreas. These results indicate that the C-terminal amide of this peptide is necessary toreveal its biological activity. 
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1. INTRODUCTION 
Pancreastatin, first isolated from porcine pancreas 
by Tatemoto et al., in 1986, is a 49 amino acid residue 
peptide with a C-terminal amide structure [1]. Pan- 
creastatin has been shown to inhibit endocrine and ex- 
ocrine pancreatic secretions [2,3]. We recently found 
that rat pancreastatin inhibited pancreatic exocrine 
secretions produced by central vagal nerve stimulation 
[4], and suggested that pancreastatin acted by means of 
inhibiting vagal efferent nerve excitation. To examine 
the biological importance of the C-terminal amide 
structure of pancreastatin, we compared the effects of 
a synthetic rat pancreastatin C-terminal fragment 
(26-51) with or without a C-terminal amide structure 
on pancreatic exocrine secretions in conscious rats. 
2. MATERIALS AND METHODS 
A rat pancreastatin C-terminal fragment (26-51) with or without 
a C-terminal amide was synthesized using Fmoc-DMBH-resin and 
Fmoc-glycine-O-HMP-resin, respectively [5,6]. 2-Deoxy-D-glucose 
(2DG) was purchased from Sigma, St. Louis, MO. 
2.1. Animal preparations 
Male Wistar rats (314-330 g) were prepared with cannulae drain- 
ing bile and pancreatic juice (BPJ) separately and with a duodenal 
cannula to return BPJ to the intestine. The operative procedures used 
have been described previously in detail [7]. After the operation, rats 
were placed in modified Bollman-type restraint cages. Experiments 
were conducted on the fourth postoperative day after 5 h fasting in 
conscious rats. 
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2.2. Experimental protocols 
BPJ was collected separately at30-min intervals and the volume of 
pancreatic juice was determined with a Hamilton syringe. Twenty 
microliters of pancreatic juice was taken for protein assay, and the 
rest of the pancreatic juice was mixed with bile and infused into the 
duodenum by a syringe pump (Harvard Apparatus Compact Infusion 
Pump, Harvard Apparatus, Southnatick, MA) during the next 
30 rain. After the 90-min basal collection, 75 or 15 mg/kg of 2DG 
was injected as a bolus. The infusion of pancreastatin was started at 
a rate of 1 ml/h 60 min prior to the injection of 2DG. 
2.3. Assays 
The protein concentration i  pancreatic juice was determined by 
optical density at 280 nm of samples diluted 200 times in 0.04 M Tris 
buffer, pH 7.8 and its output per 30 min was estimated. 
2.4. Analysis of data 
Values were expressed as the mean _+ SE. Results were analyzed by 
multiple analysis of variance (MANOVA) with repeated measures 
with respect to the treatment and time, followed by Duncan's multi- 
ple range test, or one-way analysis of variance (ANOVA) followed by 
Newman-Keul's multiple comparison test, where appropriate. A
value of P < 0.05 was considered significant. 
3. RESULTS 
3.1. Stimulatory effect of 2-deoxy-D-glucose on rat 
pancreas 
The injection of 75 mg/kg of 2DG significantly in- 
creased pancreatic juice flow and protein output 
(Fig. 1). The smaller dose of 2DG (15 mg/kg) produc- 
ed smaller but significant increases in fluid and protein 
outputs (Table I). 
3.2. Effect of rat pancreastatin with a C-terminal 
amide on 2DG-stimulated pancreatic secretions 
The continuous infusion of pancreastatin with a C- 
terminal amide (100 pmol/kg per h) inhibited the pan- 
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Fig. 1. Changes in protein secretions produced by 2DG injection 
(75 mg/kg) with 100 pmol/kg per h of pancreastatin (PST) with a C- 
terminal amide and with 1000 pmol/kg per h of pancreastatin 
without a C-terminal amide. The F value obtained by repeated 
measures MANOVA for three treatments was F2.18 = 6.29, P < 0.01. 
The number of animals is shown in Table I. 
creatic responses to both doses of 2DG stimulation 
(Fig. 1 and Table I). Responses to the smaller dose of 
2DG were completely abolished by pancreastatin 
(Table I). 
3.3. Effect of rat pancreastatin without a C-terminal 
amide on 2DG-stimulated pancreatic exocrine 
secretions 
In contrast, rat pancreastatin without a C-terminal 
amide at a dose of 100 pmol/kg per h did not inhibit 
pancreatic secretions timulated by 75 mg/kg of 2DG 
(Table I). Moreover, we examined the effect of a 10 
times higher dose of this peptide on pancreatic secre- 
Table I 
Increments of protein outputs timulated by 2DG with and without 
rat pancreastatin fragments 
Doses of 2DG Protein output (mg/1.5 h) 
75 mg/kg 15 mg/kg 
Without pancreastatin 
Pancreastatin with C-terminal 
amide (100 pmol/kg per h) 
Pancreastatin without C-terminal 
amide (100 pmol/kg per h) 
Pancreastatin without C-terminal 
amide (1000 pmol/kg per h) 
28.9 +_ 2.1 11.1 +__ 2.1 
(n = 9) (n = 5) 
11.6 ± 3.0* 0.8 ± 0.9* 
(n = 6) (n = 5) 
22.8 _+ 2.1 not tested 
(n = 7) 
30.3 + 6.4 6.2 ± 3.1 
(n = 6) (n = 6) 
Values were calculated as follows: the sum of values during 1.5 h 
after 2DG injection minus the sum of values of 1 h basal secretion 
(before the injection of 2DG) × 1.5, and expressed as mean ± SE. F 
values by ANOVA were 4.95, P <: 0.01 for 75 mg/kg per h and 4.51 
for 15 mg/kg per h. * Significantly lower than other values by 
Newman-Keul's multiple comparison test 
tions stimulated by 75 and 15 mg/kg of 2DG. No effect 
on the pancreatic secretion was observed (Fig. 1 and 
Table I). 
4. DISCUSSION 
The mechanism of 2DG stimulation of the vagal ef- 
ferent nerve is believed to be the competition of 2DG 
with glucose for cell membrane transfer esulting in in- 
tracellular glucopenia. Pancreastatin inhibits this 
stimulation. The present results indicate that in order to 
elicit inhibitory bioactivity on pancreatic exocrine 
secretion, a C-terminal carboxyl-amidated structure of 
pancreastatin is necessary. In a recent study, Greeley et 
al. [8] reported that chromogranin A, which is con- 
sidered to be a precursor of pancreastatin [9], inhibited 
insulin release from isolated rat pancreas although a 
10-fold higher concentration of chromogranin A than 
pancreastatin was needed. Chromogranin A is an acidic 
glycoprotein of about 50 kDa [9] lacking a C-terminal 
amide structure. In the present study, we could not 
observe any inhibitory effect when a 10 times higher 
dose of pancreastatin without a C-terminal amide was 
applied, whereas 100 pmol/kg per h of pancreastatin 
with a C-terminal amide could elicit an inhibitory effect 
on the pancreatic exocrine secretion. Therefore, we 
propose that pancreastatin acquires its inhibitory 
bioactivity on the exocrine pancreas by proteolytic pro- 
cessing of chromogranin A and amidation of the 
carboxy-terminal of pancreastatin [10]. 
REFERENCES 
[1] Tatemoto, K., Efendic, S., Mutt, V., Makk, G., Feistner, G.J. 
and Barchas, J.D. (1986) Nature 324, 476-478. 
[2] Efendic, S., Tatemoto, K., Mutt, V., Quan, C. and Chang, D. 
(1987) Proc. Natl. Acad. Sci. USA 84, 7257-7260. 
[3] Funakoshi, A., Miyasaka, K., Nakamura, R., Kitani, K. and 
Tatemoto, K. (1989) Regul. Pept. 25, 157-166. 
[4] Miyasaka, K., Funakoshi, A. and Kitani, K. (1989) Pancreas 4, 
631 (abstract). 
[5] Funakoshi, A., Miyasaka, K., Kitani, K., Funakoshi, S., 
Tamamura, H., Fujii, N. and Yajima, H. (1989) Biochem. Bio- 
phys. Res. Commun. 158, 844-849. 
[6] Funakoshi, S., Tamamura, H., Fujii, N., Yoshizawa, K., 
Yajima, H., Miyasaka, K., Funakoshi, A., Ohta, M., lnagaki, 
Y. and Carpino, L.A. (1988) J. Chem. Soc. Chem. Commun. 
1588-1590. 
[7] Miyasaka, K. and Green, G.M. (1984) Gastroenterology 86, 
114-119. 
[8] Greeley, G.H., Thompson, J.C., Ishizuka, J., Cooper, C.W., 
Levine, M.A., Gorr, S.V. and Cohn, D.V. (1989) 
Endocrinology 124, 1235-1238. 
[9] lacango, A.L., Okayama, H. and Eiden, L.E. (1988) FEBS 
Lett. 227, 115-121. 
[10] Funakoshi, S., Tamamura, H., Ohta, M., Yoshizawa, K., 
Funakoshi, A., Miyasaka, K., Tateishi, K., Tatemoto, K., 
Nakano, I., Yamima, H. and Fujii, N. (1989) Biochem. Bio- 
phys. Res. Commun. 164, 141-148. 
280 
